Marta Figueiredo, PhD, science writer —

Soleno Therapeutics’ investigational oral therapy diazoxide choline controlled-release (DCCR) failed to significantly lower excessive appetite, but it did improve body composition and behavior in Prader-Willi syndrome (PWS) patients, top-line data from a Phase 3 trial show. Notably, excessive appetite (hyperphagia) — the hallmark symptom of PWS —…

Prader-Willi syndrome (PWS) patients have earlier-than-normal changes in body mass — associated with an increased risk of obesity, metabolic syndrome, and type 2 diabetes — which can be delayed with growth hormone (GH) treatment, a study shows. The study, “Early adiposity rebound in patients with Prader-Willi…

Obstructive sleep apnea is the most frequent sleep breathing disorder in Prader-Willi syndrome (PWS) pediatric patients, according to an Italian study. The results suggest that sleep disorders may be more severe and frequent in PWS patients than previously thought, stressing the importance of larger studies to clarify this and to…